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Objective: The aim of the present study is to compare the accuracy in using laboratory data
or clinical factors, or both, in predicting probability of dying within 7 days of hospice admission
in terminal cancer patients.
Methods: We conducted a prospective cohort study of 727 patients with terminal cancer.
Three models for predicting the probability of dying within 7 days of hospice admission were
developed: (i) demographic data and laboratory data (Model 1); (ii) demographic data and
clinical symptoms (Model 2); and (iii) combination of demographic data, laboratory data and
clinical symptoms (Model 3). We compared the models by using the area under the receiver
operator curve using stepwise multiple logistic regression.
Results: We estimated the probability dying within 7 days of hospice admission using the
logistic function, P ¼ Exp(bx)/[1 þ Exp(bx)]. The highest prediction accuracy was observed in
Model 3 (82.3%), followed by Model 2 (77.8%) and Model 1 (75.5%). The log[probability of
dying within 7 days/(1 2 probability of dying within 7 days)] ¼ 26.52 þ 0.77   (male ¼ 1,
female ¼ 0) þ 0.59   (cancer, liver ¼ 1, others ¼ 0) þ 0.82   (ECOG score) þ 0.59   (jaun-
dice, yes ¼ 1, no ¼ 0) þ 0.54   (Grade 3 edema ¼ 1, others ¼ 0) þ 0.95   (fever, yes¼ 1,
no ¼ 0) þ 0.07   (respiratory rate, as per minute) þ 0.01   (heart rate, as per minute) 2
0.92   (intervention tube ¼ 1, no ¼ 0) 2 0.37   (mean muscle power).
Conclusions: We proposed a computer-assisted estimated probability formula for predicting
dying within 7 days of hospice admission in terminal cancer patients.
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INTRODUCTION
‘How much longer will my relative live, can he (she) pass
this festival, doctor?’ is a question often raised by family
caregivers in hospice. Knowing how long one will live
allows the individual to bring closure to personal and
family matters. An accurate prognostication can also help
physicians in planning for appropriate care options those
respect the wishes of the patients and their families. Duration
of patients’ survival after hospice enrollment is an important
outcome indicator in end-of-life care because it is relevant to
the cost of care and quality of patients received (1). It was
also associated with families’ perception of helpfulness and
responsiveness from hospice services. Furthermore, late
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disorder during the ﬁrst year of bereavement (2).
In the present study, late referral was deﬁned as initiation
of hospice care at  7 days before death (3). In Taiwan, late
referral for inpatient hospice care was reported to be 32.5% in
2004 (4), which is similar to the 30.8% reported in the US
national statistics in 2007 (5), 29–36% reported by Virnig
et al. (6) and 35.1% reported by Farnon and Hofmann (7).
When patients were enrolled in hospice with ,7d a y s ,
hospice team often did not have enough time to become
familiar with patients and their home situation. The goal for
comprehensive care such as patients’ wish to die at home
might be difﬁcult to be fulﬁlled (8). Part of the explanation
for late referral can be attributed to difﬁculties in establish-
ing an accurate prognosis (9).
Clinicians are usually optimistic in estimating survival
prognosis (10–12). A number of prognostic scales are avail-
able to help improve the estimation of survival in terminal
cancer patients. They can be grouped into two categories
according to the parameters of scales. The ﬁrst category
focuses on clinical variables and performance status includ-
ing the Morita’s Palliative Prognostic Index (PPI) (13),
Stone’s PPI (14) and Chuang’s Prognostic Score (CPS) (15).
The second category focuses on clinical variables, perform-
ance status, clinical prediction of survival and laboratory
data. They include the Pirovano’s Palliative Prognostic Score
(PaP) (12) and the Bozcuk’s Intrahospital Cancer Mortality
Risk Model (ICMRM) (16).
Clinical variables have been considered as better predic-
tors of time to death than quality of end-of-life evaluation
for terminal patients (17). However, few scales based solely
on the laboratory data have been described in literature.
Comparison of prediction accuracy between clinical factors
and laboratory data was seldom discussed. The purpose of
our study is to compare the accuracy in using laboratory data
or clinical factors, or both, in predicting dying within 7 days
of hospice admission for terminal cancer patients and to
develop a computer-assisted model for prediction.
PATIENTS AND METHODS
We conducted a prospective, observational cohort study of
727 terminal cancer patients in a hospice ward at the
Buddhist Dalin Tzu Chi General Hospital, Chiayi, Taiwan,
from November 2004 to May 2007. Patients with incurable
cancer were referred from other wards of the same hospital,
other hospitals or from patients’ homes. The decision to
admit a patient was based on an initial assessment according
to the government regulations for hospice and palliative care.
For the purpose of respecting the medical wishes of patients
at the terminal stage of an incurable illness and safeguarding
their rights, the ‘Hospice-Palliative Care Act’ was promul-
gated in Taiwan on 7 June 2000. Patient at terminal stage
may establish will of consent in choice of hospice-palliative
care. One of the main points of the Act is to allow a
competent patient to refuse resuscitation attempts (18). The
Bureau of the National Health Insurance also issued new
reimbursement regulations effective from 1 July 2000 to
provide inpatient hospice care to cancer patients who are
recognized as incurable and are willing to receive hospice
care. Recruitment of patients and design of the present study
were approved by the Institutional Review Board of
Buddhist Dalin Tzu Chi General Hospital (Nos B09303011
and B09502017). Written informed consents were obtained.
Data on demographic characteristics, the presence and
severity of clinical symptoms and signs, laboratory measure-
ment and survival were collected by a team of experienced
staff comprising physicians and senior nurses. All data were
collected within 24 h of hospital admission and the accuracy
of the data was rechecked in weekly team meeting. Eighteen
symptoms and signs identiﬁed from previous studies (19–
21) were assessed. Symptoms noted included pain, dyspnea,
fatigue/tiredness (fatigue is perceived as unusual, abnormal
or excessive whole-body tiredness, disproportionate to or
unrelated to activity or exertion) (22), nausea, vomiting and
constipation were graded according to the patients or care-
giver descriptions, as follows: 0, never happened; 1, mild
and seldom happened; 2, moderate or sometimes happened;
3, severe or continuously happened. Clinical signs for weight
loss in the past 3 months, edema, ascites, jaundice and cog-
nitive status, and the degree of severity were graded accord-
ing to the clinical examination results: weight loss in the
past 3 months (score as 0, no; 1,  5%; 2, 5–10%; 3,  10%
as recalled by the patient or caregiver), edema (score as 0,
no; 1, less than 1/2 ﬁnger breadth; 2, 1/2–1 ﬁnger breadth;
3,  1 ﬁnger breadth), ascites (score as 0, no; 1, only by
ultrasound; 2, shifting dullness by physical examination; 3,
umbilical protrusion), jaundice (score as 0, no; 1, slightly
yellowish; 2, remarkably yellow; 3, deeply yellow or green-
ish) and cognitive status (score as 0, clear; 1, lethargy; 2,
confusion or delirium; 3, comatose) (23–25). Other clinical
signs including heart rhythm, poor appetite, medication for
insomnia, fever, pressure sore, intervention tube placement
and muscle power were evaluated according to their operat-
ing deﬁnitions: heart rhythm (irregular vs. regular), poor
appetite (yes vs. no; yes deﬁned as ,500 cc of milk or ,2
bowls of porridge by mouth or tube feeding within 24 h of
admission), medication for insomnia (yes vs. no), fever (yes
vs. no; yes deﬁned as core temperature  37.58C), interven-
tion tube placement [yes vs. no; yes deﬁned as had the inter-
vention tube, e.g. percutaneous nephrostomy (PCN),
percutaneous transhepatic cholangiodrainage (PTCD), pig
tail for pleural effusion or ascites drainage, and feeding tube
except nasogastric (NG) tube], and muscle power was calcu-
lated as the sum of muscle power of each extremity divided
by four, muscle powers are graded using the Medical
Research Council (MRC) scale of 0–5: 5, normal power; 4,
moderate movement against resistance; 3, movement against
gravity but not against resistance; 2, movement with gravity
eliminated; 1, ﬂicker of movement; 0, no movement. An
additional 13 laboratory variables were examined, including
450 Model for predicting probability of dying within 7 days of hospice admissionwhite blood cell count, differential cell percentages, hemo-
globin, blood urea nitrogen (BUN), creatinine, serum gluta-
mic oxaloacetic transaminase (SGOT), serum glutamic
pyruvate transaminase (SGPT), total bilirubin, albumin,
serum sodium, serum potassium, corrected calcium and
blood sugar. Time to death in days of subjects was recorded.
When there was difﬁculty in verbal communication with
patients, their status was obtained from their caregivers.
STATISTICAL ANALYSIS
Statistical analyses were conducted using the SAS
w software,
Version 9.1.3 (SAS Institute Inc., Cary, NC, USA) and R
2.6.1 (R Foundation for Statistical Computing, Vienna,
Austria) (http://www.r-project.org). Log-rank test was used
for different group survival comparison. Univariate logistic
regression was used for selecting signiﬁcant variables associ-
ated with dying within 7 days of hospice admission.
Model-ﬁtting techniques for multiple logistic regression
analysis, including (i) stepwise variable selection, (ii) the
Hosmer–Lemeshow goodness-of-ﬁt test and (iii) regression
diagnostics including variance inﬂation factor were applied
to assure the quality of analyses. Receiver operating charac-
teristic (ROC) curves were employed for comparing the
different models. Three prediction models for dying within 7
days were developed: (i) demographic data and laboratory
data (Model 1); (ii) demographic data and clinical symptoms
(Model 2); and (iii) combination of demographic data, lab-
oratory data and clinical symptoms (Model 3). All statistical
assessments were two-sided and evaluated at the 0.05 level
of signiﬁcant difference.
RESULTS
The median time to death of the 727 terminal cancer patients
enrolled in the study was 17 days. Male had poorer survival
than female (P ¼ 0.002). Time to death of  7d a y so c c u r r e di n
103 (24.0%) males and 49 (16.8%) females. The survival prob-
ability at 1 week after admission was 79% (Fig. 1). The demo-
graphic characteristics of the subjects are shown in Table 1.
There was no difference in time to death between different age
groups (P ¼ 0.767). Bone (P ¼ 0.009) and liver (P , 0.001)
metastases signiﬁcantly reduced time to death (Table 1). The
different severities of clinical symptoms and signs are listed in
Table 2 and the P values of log-rank tests were all ,0.05. Sex,
liver cancer, respiratory rate, heart rate, Grade 3 edema, muscle
Table 1. Characteristics of the study population (n ¼ 727)
Variable n (%) P
Survival days, median (mean+SD) 17 (30.3+42)
Admission days, median (mean+SD) 10 (12.4+9)
Sex
Female 294 (40.4) 0.002
Male 433 (59.6)
Age (years)
40 32 ( 4.4) 0.767
40–64 285 (39.2)
 65 410 (56.4)
Diabetes 212 (29.2) 0.714
Hypertension 299 (41.1) 0.889
Admitted from
Emergency Room 272 (37.4) 0.158
Outpatient department 216 (29.7)
Oncology department 113 (15.5)
Other outpatient department 126 (17.3)
Cancer
Lung 132 (18.2) ,0.001
Liver 140 (19.3)
Colon 83 (11.4)
Stomach 41 ( 5.6)
Head Neck cancer 97 (13.4)
Pancreas 29 ( 4.0)
Male genitourinary 24 ( 3.3)
Female genitourinary 46 ( 6.3)
Breast 25 ( 3.4)
Esophagus 19 ( 2.6)
Unknown and others 91 (12.5)
Metastasis
Bone 189 (26.0) 0.009
Lung 124 (17.1) 0.822
Liver 140 (19.3) ,0.001
Brain 67 ( 9.2) 0.244
Operation 319 (43.9) 0.015
Chemotherapy 381 (52.4) 0.677
Radiotherapy 259 (35.6) ,0.001
P, P value of log-rank test; SD, standard deviation.
Figure 1. The Kaplan–Meier survival curve.
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creatinine, albumin, SGOT and SGPT were signiﬁcant factors
for predicting dying within 7 days of hospice admission by uni-
variate logistic analysis (Table 3).
From laboratory variables and demographic data, four sig-
niﬁcant factors were identiﬁed to form Model 1 through step-
wise logistic regression. The factors were hemoglobin, BUN,
SGOT and albumin. From clinical symptoms and signs and
demographic data, 10 signiﬁcant prognostic clinical factors
were identiﬁed to form Model 2. The factors were sex, hepa-
tocellular carcinoma, fever, Grade 3 edema, jaundice, inter-
vention tubes, ECOG scale, mean muscle power, heart rate
and respiratory rate. The 10 signiﬁcant factors identiﬁed to
form Model 3 were sex, intervention tubes, Grade 3 edema,
ECOG score, mean muscle power, hemoglobin, BUN,
SGOT, respiratory rate and heart rate (Table 4).
According to the logistic model:
log
P
1   P

¼ b0 þ b1x1 þ b2x2 þ   
þ bnxn
¼ bX ðFunction 1Þ
P ¼
ebX
1 þ ebX ðFunction 2Þ
where P is the probability of event, b0 the intercept, bn the
parameter and xn the variable.
We proposed a computer-assisted estimated probability
(CEP) for predicting dying within 7 days of hospice admis-
sion in terminal cancer patients. The formula based on
Model 2 is:
log½ðP=ð1   PÞ  ¼  6:52 þ 0:77  ð male ¼ 1; female
¼ 0Þþ0:59  ð cancer, liver ¼ 1;others
¼ 0Þþ0:82  ð ECOG scoreÞþ0:59
 ðjaundice, yes
¼ 1;no ¼ 0Þþ0:54  ð Grade 3 edema
¼ 1;others ¼ 0Þþ0:95  ðfever;yes
¼ 1;no
¼ 0Þþ0:07
 ð respiratory rate, as per minuteÞ
þ 0:01  ð heart rate, as per minuteÞ
  0:92  ð intervention tube
¼ 1;no
¼ 0Þ 0:37  ð mean muscle powerÞ
When the cut-off score (P) was .0.6, the positive predic-
tive value and the negative predictive value for patients dying
within 7 days of hospice admission were 0.74 and 0.83.
We compared the accuracy of these three models by ROC
curves (Fig. 2). The area under the curve for Model 1 was
75.5%, Model 2 was 77.8% and Model 3 was 82.3%. Model
3 exhibited the best predictor value in comparison with the
other two models (P ¼ 0.005) and the trend was also signiﬁ-
cant (P ¼ 0.002). The programming code for probability
Table 2. Prevalence of signiﬁcant clinical signs by the symptoms/signs
severity
Clinical signs Prevalence by severity (0/1/2/3) P





Body weight loss 40/260/252/174 0.003
Ascites 483/123/66/55 ,0.001
P, P value of log-rank test.
aECOG score is 1–4.
Table 3. Univariate logistic regression for the probability of dying within 7
days of hospice admission in terminal cancer patients
Variable P OR 95% CI
Age (per year) 0.084 1.01 1.00–1.03
Sex (male vs. female) 0.020 1.57 1.07–2.29
Liver cancer vs. other cancer ,0.001 2.21 1.47–3.32
Lung cancer vs. other cancer 0.553 1.15 0.73–1.79
Diabetes history (yes vs. no) 0.674 0.91 0.58–1.42
Hypertension history (yes vs. no) 0.226 0.77 0.50–1.18
ECOG score (per score) ,0.001 2.46 1.85–3.28
Respiratory rate (per 1/min) ,0.001 1.08 1.04–1.12
Heart rate (per 1/min) ,0.001 1.02 1.01–1.03
Edema (Grade 3 vs. others) ,0.001 2.03 1.36–3.03
Mean muscle power (per score) ,0.001 0.59 0.49–0.70
Fever (yes vs. no) 0.534 1.14 0.75–1.74
Jaundice (yes vs. no) ,0.001 2.37 1.63–3.44
Intervention tube (yes vs. no) 0.029 0.43 0.20–0.92
WBC (per 10
3/ml) 0.609 1.001 0.996–1.006
Hemoglobin (per mg/dl) 0.305 1.05 0.96–1.14
Glucose (per mg/dl) 0.810 1.000 0.997–1.002
BUN (per mg/dl) ,0.001 1.03 1.02–1.04
Creatinine (per mg/dl) ,0.001 1.43 1.22–1.67
Albumin (per g/dl) 0.008 0.65 0.47–0.89
SGOT (per 10 IU/l) ,0.001 1.04 1.02–1.05
SGPT (per 10 IU/l) ,0.001 1.04 1.02–1.05
OR, odds ratio; WBC, white blood cell; BUN, blood urea nitrogen; SGOT,
serum glutamic oxaloacetic transaminase; SGPT, serum glutamic pyruvate
transaminase.
452 Model for predicting probability of dying within 7 days of hospice admissioncalculation based on the ﬁtted model in the R environment
(http://www.r-project.org/) is provided in Appendix 1.
Validations were performed using split data sets, in which
the model was trained on a randomly selected subset of half
of the data and tested on the remaining data. Validation tests
were repeated 10 times for different selections of training and
test data. The models produced were similar to the original
and performed nearly as well on test data as on training data.
DISCUSSION
The probability of dying within 7 days of hospice admission
was 20.9%, which is better than the ﬁndings of 33.5% in
Taiwan in 2004. Part of the reason is the new policy of
integrating hospice service into acute care wards issued by
the Bureau of Health Promotion, Department of Heath,
Taiwan, in 2005. The new policy has a potential to expand
the utilization of hospice care by cancer decedents. Barriers
to accessing hospice care are complex and often overlapping,
and some factors are related to physicians. For example,
physicians often delay patients’ referral to hospice because
of their often over-optimistic view of their patients’ progno-
sis shortly before death (26). By improving the accuracy of
prediction of dying within 7 days of hospice admission, we
hope to assist physicians in making a more realistic survival
prediction in their patients.
The accuracy of predicting probability of dying within 7
days of hospice admission by the three models was signiﬁ-
cantly different. Model 2 (clinical factors and demographic
data) was more accurate than Model 1 (laboratory tests and
demographic data). The laboratory data were derived from
the biochemical and blood tests of admission routine and it
could supplement the prognostic power of clinical and demo-
graphic variables.
Previous studies have identiﬁed many putative prognostic
factors in patients with advanced cancer, including clinical
estimates of survival, demographic and clinical variables and
laboratory parameters (27,28). Some groups have constructed
prognostic scales using different combinations of these vari-
ables (12,16). Model 3 was the best predictive model and
included performance status (ECOG score), ﬁve clinical vari-
ables (edema with degree 3 severity, mean score of muscle
power, heart rate, respiratory rate and intervention tube), sex
and three laboratory parameters (hemoglobin, BUN and
SGOT). The factors of ECOG, edema with a degree 3
Table 4. Three computer-assisted estimated probability models for the prediction of dying within 7 days of hospice admission in terminal cancer patients
Variable Model 1 Model 2 Model 3
b P OR b P OR b P OR
Intercept 22.20 0.001 26.52 ,0.001 27.76 ,0.001
Hemoglobin (per mg/dl) 0.11 0.028 1.12 0.14 0.006 1.15
BUN (per mg/dl) 0.03 ,0.001 1.03 0.03 ,0.001 1.03
Albumin (per g/dl) 20.50 0.009 0.61
SGOT (per 10 IU/l) 0.03 0.001 1.03 0.03 ,0.001 1.03
Sex (male vs. female) 0.77 0.001 2.17 0.68 0.004 1.98
Intervention tube (yes vs. no) 20.92 0.024 0.40 20.93 0.027 0.40
Edema (Grade 3 vs. others) 0.54 0.019 1.72 0.61 0.013 1.83
ECOG (per score) 0.82 ,0.001 2.27 0.76 ,0.001 2.14
Muscle power (per score) 20.37 0.001 0.69 20.30 0.009 0.74
Cancer (liver vs. others) 0.59 0.023 1.81
Fever (yes vs. no) 0.95 0.040 2.59
Jaundice (yes vs. no) 0.59 0.011 1.81
Respiratory rate (per 1/min) 0.07 0.005 1.07 0.06 0.019 1.06
Heart rate (per beat/min) 0.01 0.034 1.01 0.01 0.024 1.01
Figure 2. The receiver operating characteristic curve of three computer-
assisted estimated probability models for prediction dying within 7 days of
hospice admission in terminal cancer patients: Model 1, laboratory data and
demographic data; Model 2, clinical factors and demographic data; Model 3,
clinical factors, laboratory data and demographic data.
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vious studies (15–17,29–32). We identiﬁed ﬁve useful prog-
nostic factors in this study: (i) the mean score of muscle
power can express the weakness or energy level of a patient.
A lower muscle power score correlated with a shorter pre-
dicted survival. (ii) For the basic vital signs of respiratory
and heart rate, higher rates were signiﬁcantly correlated with
increased probability of mortality within 1 week, similar to
an earlier study (33). (iii) Intervention tube, e.g. PCN,
PTCD, pig tail drainage, feeding tube excluding NG tube,
indicated that the patients were receiving aggressive inter-
ventions before being admitted to the palliative care unit and
was associated with longer survival. Patients with placement
of intervention tube had signiﬁcantly lower risk for death in
7 days after admission in our study. The placement of inter-
vention tube might prolong the survival days of the patients
after the clinical issues had solved by the placement of the
tube or that the placement of intervention tube was able to
help the patients to live better. (iv) One unique ﬁnding in
this study was that the higher hemoglobin indicated a higher
probability of within 7-day survival, whereas the low hemo-
globin group had a worse survival after 2 weeks. Anemia
was a predictive factor for shorter survival in most studies,
as measured in weeks to months survival (27). (v) BUN was
also identiﬁed as a predictor in the previous study (34).
Terminal azotemia refers to the dehydration status and acute
renal failure involved in the dying process. (vi) SGOT is the
prognostic factor in patients with hepatocellular carcinoma
(35), which is the leading cause of death in Taiwan for more
than 20 years; and it is also identiﬁed in the other
study (36).
Previous studies have discussed prognostic tools for pre-
diction of survival from weeks to months in advanced cancer
patients with disparate results (37). However, prediction of
dying within 7 days of hospice admission has rarely been
discussed. The method of CEP can easily be calculated
within 24 h of patient admission and can serve as a useful
tool to assist estimation of survival prediction.
Limitations of this study include recall bias and misclassi-
ﬁcation error. When the patients could not accurately recall
their body weights 3 months before the study, calculation of
weight loss had to be based on the information provided by
patients’ family members. Moreover, misclassiﬁcation error
may be present in the grading of the clinical signs such as
severity of ascites, jaundice and cognitive status. In addition,
data regarding symptoms on the regular chart such as extre-
mity cyanosis, self-conscious dying and biologic parameters
such as serum electrolytes, B12/C-reactive protein (38),
serum lactate dehydrogenase and alkaline phosphatase were
not included in data analysis.
In conclusion, a CEP that utilized clinical factors, demo-
graphic factors and laboratory data were developed for
patients with advanced cancer. We suggested using Model 2
as a readily accessible tool for making prediction and using
Model 3 if laboratory data are available. It is hope that the
CEP prognostic scale can assist clinicians in making accurate
survival prediction and thus able to form treatment decisions
that minimize harm and discomfort in patients.
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Appendix 1. Programming code in R for calculating
probability of dying within 7 days after hospice
admission in patients with terminal cancer
Substitute the values for the variables X1 to X10 in the
regression equation to calculate the probability of dying
within 7 days after hospice admission.
yhat ,2 (26.52 # constant
þ0.77*X1 # X1 ¼ sex (male ¼ 1, female ¼ 0)
þ0.59*X2 # X2 ¼ cancer (liver cancer ¼ 1,
others ¼ 0)
þ0.82*X3 # X3 ¼ ECOG score
þ0.59*X4 # X4 ¼ jaundice (yes ¼ 1, no ¼ 0)
þ0.54*X5 # X5 ¼ edema (1 if edema ¼ grade
3, 0 if otherwise)
þ0.95*X6 # X6 ¼ fever (yes ¼ 1, no ¼ 0)
þ0.07*X7 # X7 ¼ respiratory rate per minute
þ0.01*X8 # X8 ¼ heart rate, beat per minute
20.92*X9 # X9 ¼ intervention tube (yes ¼ 1,
no ¼ 0)
20.37*X10 # X10 ¼ mean muscle power score
phat ,-1 /
(exp(-(yhat)) þ 1)
phat # copy these syntax and paste on
the R console
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